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Background: We report necrotizing scleritis as a serious complication of a cosmetic eye whitening procedure that
involves the use of intraoperative and postoperative topical mitomycin C.
Findings: This is a single case report. A 59-year-old Caucasian male with a history of blepharitis status post
uncomplicated LASIK refractive surgery reported chronic conjunctival hyperemia for 15 years prior to undergoing a
cosmetic eye whitening procedure. He presented to our clinic 12 months after the cosmetic eye whitening
procedure with progressive bilateral necrotizing scleritis and scleral calcification.
Conclusions: Chronic conjunctival hyperemia may prompt patients to seek surgical correction with cosmetic eye
whitening procedures. However, conjunctival hyperemia secondary to tear deficiency and evaporative dry eye may
predispose to poor wound healing. Serious complications including necrotizing scleritis may result from cosmetic
eye whitening procedures and the use of topical mitomycin C.
Keywords: Necrotizing scleritis, I-BRITE, Cosmetic eye whitening, Mitomycin CFindings
Introduction
Cosmetic eye whitening procedures are a relatively new
cosmetic treatment option for patients concerned about
the appearance of chronic conjunctival hyperemia. There
are a limited number of centers in the USA and world-
wide that perform eye whitening procedures. The eye
whitening procedure is similar to the conjunctivoplasty
performed in pterygium excision but involves dissection
and cautery of the conjunctiva tissue down to the level
of episclera and portions of Tenon’s capsule with intra-
operative or postoperative use of topical mitomycin C [1,2].
The out-of-pocket expense for the procedure is approxi-
mately US$3,000 to 5,500 per eye [1].
Kim reported a technique of regional conjunctivectomy
with postoperative mitomycin C 0.02%, known commer-
cially as Cosmetic Eye Whitening™ (Seer & Partner Eye* Correspondence: tgan1@jhmi.edu; jthorne@jhmi.edu
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management includes topical application of 0.02%
mitomycin C four times daily for 2 to 5 days, antibiotic
eye drops, and topical corticosteroid eye drops [3]. The
desired outcome is for regenerated conjunctival tissue to
appear translucent without the excessive vascularization
that causes the appearance of red eyes.
Serious complications related to the use of mitomycin C
in eye whitening procedures have been reported in patients
undergoing the Cosmetic Eye Whitening™ procedure, in-
cluding avascularity of the sclera, chronic conjunctival epi-
thelial defects, scleral thinning with or without calcified
plaques, adhesions of Tenon’s capsule to the conjunctiva at
the extraocular muscle insertion site, extraocular muscle
fiber exposure, and diplopia [4].
We report a case of bilateral necrotizing scleritis after the
I-BRITE™ cosmetic eye whitening procedure performed in
the USA. To our knowledge, this represents the first
documented case of a bilateral necrotizing scleritis as a
complication of an eye whitening procedure.
Case presentation
A 59-year-old Caucasian male presented to our clinic in
February of 2011 for a second opinion regarding the devel-
opment of white spots that he noticed in the inner cornern Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 2 Necrotizing scleritis with associated calcium plaque,
left eye.
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hay fever. He had uncomplicated LASIK refractive surgery
in both eyes in 1995. He reported a 15-year history of
chronic red eyes and irritation which prompted him to
undergo the I-BRITE™ (Boxer Wachler Vision Institute,
Beverly Hills, CA, USA) cosmetic eye whitening surgery in
both eyes in February 2010.
Initially after the eye whitening procedure, he noticed
decreased redness in both eyes. Four to five months
following the procedure, however, he noted ‘white spots’
appearing in the inner corner of both eyes. There was no
associated pain, discharge, vision change, or sensitivity to
light. He was treated by his local ophthalmologist with
cyclosporine 0.05%, olopatadine 0.1%, epinastine 0.05%,
and punctal plugs in the lower lids bilaterally without im-
provement of the white spots.
At the time of presentation, he was using ketorolac 0.5%
and artificial tears in both eyes three times daily. Uncor-
rected visual acuity at distance was 20/20 in both eyes.
Slit-lamp examination of the lids and lashes revealed mei-
bomian gland dysfunction with telangiectactic vessels along
the lid margins. Zones of markedly white conjunctivae and
sclerae were noted bilaterally. In the right medial conjunc-
tiva, there was a 2 × 1mm region of conjunctival erosion
with fluorescein uptake associated with scleral thinning and
calcium deposits (Figure 1). A prominent finding was the
occurrence of the scleral thinning in a region lacking con-
junctival, episcleral, or scleral vessels. Similarly, the medial
conjunctiva of the left eye demonstrated a 2.5 × 1mm re-
gion of conjunctival erosion and scleral melting, associated
with calcium deposits (Figures 2 and 3). There were well-
healed LASIK scars bilaterally, and there was no anterior
chamber reaction.
Aggressive lubrication with preservative-free artificial
tears and ointment was initiated, and the ketorolac was
discontinued. Over the next 4 months, there was evidence
of progressive scleral melting in both eyes. At that point, an
amniotic membrane patch graft was recommended.Figure 1 Necrotizing scleritis with associated calcium plaque,
right eye.However, the patient was reluctant to undergo further sur-
gical procedures and elected alternative medical manage-
ment with cyclosporine 1% and medroxyprogesterone
acetate 1% eye drops. He has been maintained on these eye
drops with close monitoring.
Discussion
Necrotizing scleritis with or without inflammation has
been reported as a complication of pterygium excision with
adjunctive mitomycin C therapy [5-9]. Other documented
complications from the intraoperative and postoperative
use of topical mitomycin C include scleral ulceration,
scleral calcification, scleral thinning, chemosis, delayed con-
junctival wound healing, corneoscleral melt, corneal
edema, keratitis, corneal perforation, secondary glaucoma,
corectopia, and uveitis [5-11].
Mitomycin C is an alkylating agent that inhibits DNA
synthesis. The mechanism behind necrotizing scleritis and
sclera thinning secondary to mitomycin C is thought to be
inhibition of fibroblast proliferation coupled with vascular
compromise leading to an avascular necrosis of the sclera
[7,12]. One study examined the scleral thickness and theFigure 3 Fluorescein uptake in the area of conjunctival and
sclera erosion.
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intraoperative mitomycin C. After a mean period of 6 years,
there was a fourfold decrease in the goblet cell density of
the surgical site after mitomycin C application compared to
the contralateral non-operated site [12]. This demonstrates
that mitomycin C has prolonged effects on the ocular sur-
face tissue long after discontinuation of the drug.
Cosmetic eye whitening procedures, similar to ptery-
gium excision, involve wide conjunctivectomy and
intraoperative and/or postsurgical or topical application
of 0.02% mitomycin. In a retrospective study conducted
by Rhiu et al. [4], complications were found in 44 of 48
patients (92%), including 22 patients (50%) with chronic
conjunctival epithelial defects, 21 (48%) with scleral
thinning, 19 (43%) with calcified plaques, and 10 (23%)
with avascular zones of the sclera. It is possible that
these ten patients with avascular zones may have
presented with the same clinical phenomenon as our
patient. Conversely, Kim [3] reported a much lower in-
cidence of complications, including scleral calcification
(3.9%), diplopia (1.6%), elevated intraocular pressure
secondary to postoperative topical steroid use (17.2%),
granuloma formation (8.4%), and transient decrease in
vision (7.5%) without permanent deficits noted.
In our patient, the necrotizing scleritis presented with
bilateral focal scleral thinning and calcified plaques. We
believe that the vascular compromise precipitated the
necrotizing scleritis as there was a marked scarcity of
conjunctival and sclera vessels in the affected region.
Treatment options for necrotizing scleritis secondary
to pterygium excision with mitomycin C include a
scleral patch, amniotic membrane patch graft, lamellar
corneoscleral graft, or conjunctival flap [13-15]. Five
patients in the study conducted by Rhiu et al. required a
conjunctival flap because of severe progressive scleral
thinning [4]. Our patient declined an amniotic membrane
patch graft after a discussion of the possible failure of a
conjunctival flap in an eye with compromised vasculature.
In cases of pterygium excision, Rubinfeld et al. [6]
cautioned that conditions such as acne rosacea, atopic
keratoconjunctivitis, keratoconjunctivitis sicca, Sjögren’s
syndrome, blepharitis, or herpes keratitis may predispose
to poor wound healing, making mitomycin C a precar-
ious choice of therapy in affected patients. Unfortunately,
these are many of the same conditions that cause chronic
conjunctival injection prompting patients to seek cosmetic
eye whitening procedures.
Our patient had prior LASIK surgery and blepharitis,
both of which can cause or exacerbate dry eye and may
have been the underlying cause of his chronic conjunc-
tival injection before he sought a surgical cosmetic so-
lution. Tear deficiency and evaporative dry eye may
have predisposed him to poor wound healing, in
addition to the postoperative use of topical NSAIDs.Although the technique developed by Kim in his Cos-
metic Eye Whitening™ procedure has been published
and reported, we acknowledge there may be slight
variations from the I-BRITE™ procedure that our patient
underwent which have not been published in the litera-
ture [3], such as the concentration or application time of
intraoperative mitomycin C and the concentration, dur-
ation, and frequency of the mitomycin C postoperatively.
These variations may account for why more reported
complications have not arisen in the USA from patients
who have undergone cosmetic eye whitening, or it may
be that the number of patients who have had this
procedure in the USA has not reached a significant level
in comparison to South Korea.
While elective cosmetic eye whitening procedures may
be safe in most patients, our case reaffirms that serious
complications may occur with surgical and pharmaco-
logic manipulation of the natural vasculature of the ocu-
lar surface.
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